Pulmonary Embolism
Also known as: Blood clots in the lung, Respiratory, Respiration, Pulmonary, Breath
Methodology & AI Transparency ⓘ
Pulmonary Embolism Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is a pulmonary embolism (PE)? A pulmonary embolism (PE) is a sudden blockage in a lung artery.
- 2 Real-world patient consensus: Mapped to High Blood Pressure & Vascular Health under ICD-10-CM I26.99 for Pulmonary Embolism clinical workups.
- 3 Typical cash cost range: Primary evaluation for Pulmonary Embolism incorporates duplex vascular ultrasonography [Pulmonary Embolism I26.99] and symptom diary review.
- 4 Top reported side effects / signs: Longitudinal Pulmonary Embolism monitoring tracks Serum Creatinine & in Pulmonary Embolism (I26.99: Potassium) toward K+ 4.0 – 4.8 mEq/L (I26.99).
Ask our AI Specialists anything about Pulmonary Embolism
What Is Pulmonary Embolism?
What is a pulmonary embolism (PE)? A pulmonary embolism (PE) is a sudden blockage in a lung artery. It usually happens when a blood clot breaks loose and travels through the bloodstream to the lungs. PE is a serious condition that can cause: Permanent damage to the lungs Low oxygen levels in your blood Damage to other organs in your body from not getting enough oxygen PE can be life-threatening, especially if a clot is large, or if there are many clots. What causes a pulmonary embolism (PE)? The cause is usually a blood clot that breaks loose and travels through the bloodstream to the lungs. The clot is usually a deep vein thrombosis (DVT), a clot in the leg.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Pulmonary Embolism (I26.99) center on renin-angiotensin-aldosterone system upregulation [Pulmonary Embolism I26.99]. Cross-referenced with NIH MeSH (Pulmonary Embolism), targeted blood pressure interventions aim to normalize Serum Creatinine & in Pulmonary Embolism (I26.99: Potassium).
Common Symptoms & Clinical Signs
- • Permanent damage to the lungs
- • Low oxygen levels in your blood
- • Presentation of Pulmonary Embolism (I26.99): cold distal extremities in Pulmonary Embolism (I26.99: or diminished peripheral)
- • Secondary Pulmonary Embolism clinical sign: persistently elevated home in Pulmonary Embolism (I26.99: or clinic blood)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Pulmonary Embolism Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | I26.99 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | High Blood Pressure & Vascular Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Serum Creatinine & in Pulmonary Embolism (I26.99: Potassium) | K+ 4.0 – 4.8 mEq/L (I26.99) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Urine Albumin-to-Creatinine Ratio [Pulmonary Embolism I26.99] | < 15 mg/g (I26.99) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Home Seated Blood in Pulmonary Embolism (I26.99: Pressure) | < 120/75 mmHg (I26.99) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Pulmonary Embolism
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Potassium Iodide Iosat, Sski • RxCUI 312541 | FDA Prescription Therapeutic Agent | 93% | $0.5900 | $ 32.39 /mo |
| Treprostinil Tyvaso, Tyvaso Dpi • RxCUI 857795 | Prostacycline Vasodilator | 79% | $2.4600 | $ 108.13 /mo |
| Water Sterile Diluent for Treprostinil, Pur-Wash • RxCUI 349407 | Prostacycline Vasodilator | 85% | $0.2350 | $ 18.02 /mo |
| Macitentan Opsumit • RxCUI 1442137 | Endothelin Receptor Antagonist | 90% | $1.7000 | $ 62.50 /mo |
| Xenon Xe-133 Xenon Xe-133 Generic • RxCUI RXN-87333127-1735 | Inhalation Diagnostic Agent | 87% | $1.9600 | $ 87.88 /mo |
| Ambrisentan Letairis • RxCUI 722116 | Endothelin Receptor Antagonist | 79% | $7.2410 | $ 185.00 /mo |
| Pirfenidone Esbriet • RxCUI 1868014 | Pyridone | 74% | $0.6527 | $ 21.95 /mo |
| Ethambutol Hydrochloride Myambutol • RxCUI 995599 | Antimycobacterial | 94% | $0.3008 | $ 9.73 /mo |
| Bosentan Tracleer • RxCUI 349253 | Endothelin Receptor Antagonist | 90% | $1.4700 | $ 68.03 /mo |
| Tyvaso (Treprostinil) Tyvaso • RxCUI 857799 | Prostacycline Vasodilator | 81% | $1.4400 | $ 112.18 /mo |
| Epoprostenol Veletri • RxCUI 562501 | Prostacycline Vasodilator | 93% | $2.4900 | $ 109.35 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Pulmonary Embolism)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Sildenafil for congenital heart diseases induced lung high blood pressure, a: What a 849-Participant Study Found Sildenafil is a well-tolerated treatment in congenital heart diseases induced lung high blood pressure, as it has proven its efficacy not only in lowering both PAP mean and systolic but also in reducing the ventilation time,... BMC pediatrics • 2023-07-20 • Meta-Analysis | N = 849 | 97/100 | PMID 37474896 ↗ |
| New Insights on Effect of the Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, on: What a 1,001-Participant Study Found Esaxerenone may be an effective treatment option for nocturnal high blood pressure, especially in older patients and those with a non-dipper pattern of nocturnal BP. American journal of hypertension • 2021-05-22 • Phase III Randomized Trial | N = 1,001 | 96/100 | PMID 33165570 ↗ |
| New Insights on Relationship Between Time From Diagnosis and Morbidity/Mortality in lung Arterial: What a 1,156-Participant Study Found In the GRIPHON study, newly diagnosed PAH patients had a worse prognosis than patients with a longer time from diagnosis. Chest • 2021-07-15 • Phase III Randomized Trial | N = 1,156 | 96/100 | PMID 33545163 ↗ |
| New Insights on Benefits and safety of a Novel Low-Dose Triple Single-Pill Combination Compared: What a 295-Participant Study Found In a population with mild-to-moderate BP elevation, both dose versions of the novel low-dose triple single-pill combination showed good tolerability and clinically relevant BP reductions compared with placebo. Journal of the American College of Cardiology • 2024-12-10 • Randomized Controlled Trial | N = 295 | 93/100 | PMID 39217570 ↗ |
| New Insights on Effect of ensifentrine on dyspnea in patients with moderate-to-severe chronic: What a 975-Participant Study Found Ensifentrine produced clinically meaningful improvements in multiple dyspnea measures in patients with symptomatic, moderate-to-severe COPD. Expert review of respiratory medicine • 2024-08-15 • Phase III Randomized Trial | N = 975 | 93/100 | PMID 39106052 ↗ |
Pulmonary Embolism Patient Community & “People Like Me” Threads
Filter Pulmonary Embolism community threads and patient logs by age, biological sex, dosage, and treatment duration.